DRUGRECURE ApS - CVR: 29154406

2023, DKK

27.06.2024

Bruttoresultat

-99.396'

Primær drift

-99.396'

Årets resultat

-134''

Aktiver

46.994'

Kortfristede aktiver

46.994'

Egenkapital

-803''

Afkastningsgrad

-212 %

Soliditetsgrad

-1709 %

Likviditetsgrad

6 %

Resultat

27.06.2024

Årsrapport	2023 27.06.2024	2022 03.03.2023	2021 27.06.2022	2020 03.06.2021	2019 03.06.2020	2018 31.05.2019	2017 13.06.2018	2016 14.06.2017	2015 06.06.2016
Nettoomsætning								714.000	153.000
Bruttoresultat	-99.396.000	0	-88.638.000	-121.735.000	0	-15.871.000	-9.821.000	480.000	0
Resultat af primær drift	-99.396.000	0	0	0	-55.118.000	-15.871.000	-9.821.000	-8.228.000	-9.200.000
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0	0
Finansielle indtægter	3.393.000	-27.801.000	-24.493.000	-15.241.000	0	0	0	0	0
Finansieringsomkostninger	-53.656.000	0	0	0	0	-5.495.000	-1.311.000	0	-6.000
Andre finansielle omkostninger	0	0	0	0	0	0	0	0	0
Resultat før skat	-149.659.000	-93.946.000	-145.715.000	-152.808.000	-65.585.000	-21.366.000	-11.132.000	-8.228.000	-9.206.000
Resultat	-133.501.000	-84.355.000	-140.215.000	-142.996.000	-60.085.000	-15.866.000	-5.632.000	-6.275.000	-7.189.000
Forslag til udbytte	0	0	0	0	0	0	0	0	0

Aktiver

27.06.2024

Årsrapport	2023 27.06.2024	2022 03.03.2023	2021 27.06.2022	2020 03.06.2021	2019 03.06.2020	2018 31.05.2019	2017 13.06.2018	2016 14.06.2017	2015 06.06.2016
Kortfristede varebeholdninger	0	0	0	0	0	0	382.000	116.000	1.244.000
Kortfristede tilgodehavender fra salg og tjenesteydelser	46.994.000	0	0	0	14.273.000	15.642.000	18.519.000	1.953.000	569.000
Likvider	0	0	0	0	0	0	0	0	0
Kortfristede aktiver	46.994.000	37.705.000	28.182.000	28.183.000	14.273.000	15.642.000	18.901.000	2.069.000	1.812.000
Immaterielle aktiver og goodwill	0	0	293.257.000	0	0	0	0	0	0
Finansielle anlægsaktiver	0	0	0	0	0	0	0	0	0
Materielle aktiver	0	0	0	0	0	0	0	0	0
Langfristede aktiver	0	0	0	325.841.000	0	255.165.000	151.513.000	85.866.000	56.364.000
Aktiver	46.994.000	37.705.000	321.439.000	354.024.000	355.947.000	270.807.000	170.413.000	87.935.000	58.177.000

Aktiver

27.06.2024

Passiver

27.06.2024

Årsrapport	2023 27.06.2024	2022 03.03.2023	2021 27.06.2022	2020 03.06.2021	2019 03.06.2020	2018 31.05.2019	2017 13.06.2018	2016 14.06.2017	2015 06.06.2016
Forslag til udbytte	0	0	0	0	0	0	0	0	0
Egenkapital	-803.088.000	-669.587.000	-291.975.000	-151.757.000	-8.761.000	51.323.000	67.188.000	72.820.000	8.977.000
Hensatte forpligtelser	0	0	0	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0	0
Anden langfristet gæld		0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	0	0	0	0	0	0	0	0	2.408.000
Kortfristede forpligtelser	850.082.000	707.292.000	613.414.000	505.782.000	364.708.000	219.485.000	103.225.000	15.114.000	49.200.000
Gældsforpligtelser	850.082.000	707.292.000	613.414.000	505.782.000	364.708.000	219.485.000	103.225.000	15.114.000	49.200.000
Forpligtelser	850.082.000	707.292.000	613.414.000	505.782.000	364.708.000	219.485.000	103.225.000	15.114.000	49.200.000
Passiver	46.994.000	37.705.000	321.439.000	354.024.000	355.947.000	270.807.000	170.413.000	87.935.000	58.177.000

Passiver

27.06.2024

Nøgletal

27.06.2024

Årsrapport	2023 27.06.2024	2022 03.03.2023	2021 27.06.2022	2020 03.06.2021	2019 03.06.2020	2018 31.05.2019	2017 13.06.2018	2016 14.06.2017	2015 06.06.2016
Afkastningsgrad	-211,5 %	Na.	Na.	Na.	-15,5 %	-5,9 %	-5,8 %	-9,4 %	-15,8 %
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	67,2 %	Na.
Resultatgrad	Na.	Na.	Na.	Na.	Na.	Na.	Na.	-878,9 %	-4.698,7 %
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	6,2	0,1
Egenkapitals-forretning	16,6 %	12,6 %	48,0 %	94,2 %	685,8 %	-30,9 %	-8,4 %	-8,6 %	-80,1 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-185,2 %	Na.	Na.	Na.	Na.	-288,8 %	-749,1 %	Na.	-153.333,3 %
Soliditestgrad	-1.708,9 %	-1.775,9 %	-90,8 %	-42,9 %	-2,5 %	19,0 %	39,4 %	82,8 %	15,4 %
Likviditetsgrad	5,5 %	5,3 %	4,6 %	5,6 %	3,9 %	7,1 %	18,3 %	13,7 %	3,7 %

Resultat

27.06.2024

Gæld

27.06.2024

Årsrapport

27.06.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 27.06.2024)

Information om virksomhedens regnskabsklasse:The annual report of Drugrecure ApS for 2023 has been prepared in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B and the Accounting Standard on small enterprises, as well as provisions applying to reporting class C entities. The accounting policies applied are consistent with those of last year. The annual report for 2023 is presented in kDKK

Beretning

27.06.2024

Beskrivelse af usikkerhed ved indregning eller måling:Recognition and measurement uncertainties The preparation of the financial statements requires the making of estimates and judgments that affect the reporting of assets, liabilities and expenses. The estimates and judgments are reviewed on an ongoing basis. Estimates and judgments are based on historical results and on various other assumptions, which the management believes to be reasonable under the circumstances. However, the actual results may differ significantly from the estimates. The management believes that the accounting policies relating to development costs and deferred tax involve estimates or judgments by management that could materially affect the reported financial position and results. Tax credit Due to tax credit reimbursement instalment by the Danish government, Drugrecure ApS expects to be reimbursed DKK 5,500k of the tax asset in 2024 - hence the tax receivable has been recognized in the balance sheet. The long-term deferred tax asset has been evaluated against the future income within the next three fiscal years and will not be recognised in the balance sheet.

Oplysning om usædvanlige forhold:The Company's activites is financed from it's Parent company Savara ApS, which ultimately is financed from Savara Inc. , based in the US. The Company expects to be able to repay the loan once the development of Molgramostim is finalized and the Company has commercialized the product's full potential after 2026. In the event that the product under development in the Company against management expectations should fail to be marketed and the Company should close down with no assets, the US parent company, Savara Inc. , which is financing the activities, will foregive all receivables with the Danish group companies.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:The executive board has today discussed and approved the annual report of Drugrecure ApS for the financial year 1 January - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Business review Drugrecure ApS is a 100% subsidiary of Savara ApS and part of the Savara Inc. group. Savara Inc. is a U. S.-based emerging pharmaceutical development company. The Company is focused on advancing inhalation therapies for the treatment of patients with rare pulmonary conditions. In Drugrecure ApS, the treatment is centered around Molgramostim, inhaled nebulized GM-CSF to treat Autoimmune Pulmonary Alveolar Proteinosis(a PAP).